Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.16%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +36.53%
#5 RedStone RedStone +28.90%
#6 Humanity Humanity +26.35%
#7 Codatta Codatta +22.55%
#8 Walrus Walrus +19.98%
#9 The Black Bull The Black Bull +17.02%
#10 Enso Enso +16.70%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
Rangering i aksjer #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Aksjekurs
$5.34
Sist synkronisert: 2026-08-14
Markedsverdi
$2.59M
Endring (1 dag)
-11.00%
Endring (1 år)
313.95%
Land
US
Handel Jupiter Neurosciences, Inc. (JUNS)

Kategori

Healthcare
P/S-forhold for Jupiter Neurosciences, Inc. (JUNS)
P/S-forhold per 2026 TTM: 0
Ifølge Jupiter Neurosciences, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Jupiter Neurosciences, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE